Mavacamten safety study in Korean patients with oHCM
Treatments studied
Part of Heart & circulation clinical trials.
This study checks how safe the drug mavacamten is for Korean patients with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM). It is for people who are already prescribed the drug by their doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years old or older.
- You must be prescribed mavacamten for symptomatic obstructive hypertrophic cardiomyopathy (oHCM) as approved in Korea.
- You must agree to participate in the study by signing a consent form.
- You cannot take mavacamten for a condition not approved in Korea.
- You cannot have any health condition or take any medication that makes mavacamten unsafe for you, as listed in Korean safety guidelines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether the drug mavacamten (Camzyos) improves blood flow in the heart's small vessels for people with obstructive hypertrophic cardiomyopathy. You will take mavacamten as prescribed and have a PET/CT scan to measure your heart's blood flow reserve.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This trial combines a new heart medication (mavacamten) with a procedure called radiofrequency ablation to treat a condition where the heart muscle thickens and blocks blood flow. It is for people who still have symptoms despite standard care.
This study tracks how people with obstructive hypertrophic cardiomyopathy feel and function while taking Camzyos (mavacamten). It aims to understand the real-world effects of the medication beyond clinical trials.
This study tracks the safety of Mavacamten in people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle thickens and blocks blood flow). It helps doctors understand how the drug works in everyday use in Japan.
This study looks at how mavacamten (a heart medication) works for people with obstructive hypertrophic cardiomyopathy (HCM)—a condition where heart muscle becomes too thick. Researchers will review medical records and ask patients about their experiences with the treatment.
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.